BIA 10-2474

BIA 10-2474
Clinical data
Routes of; administration	Oral
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name 3-(1-(cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide;
CAS Number	1233855-46-3;
PubChem CID	46831476;
IUPHAR/BPS	9001;
ChemSpider	41628677;
UNII	5AP1ZW859M;
CompTox Dashboard (EPA)	DTXSID901009325 ;
Chemical and physical data
Formula	C16H20N4O2
Molar mass	300.362 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C(=O)n1cnc(-c2ccc[n+]([O-])c2)c1)C1CCCCC1;
	InChI InChI=1S/C16H20N4O2/c1-18(14-7-3-2-4-8-14)16(21)19-11-15(17-12-19)13-6-5-9-20(22)10-13/h5-6,9-12,14H,2-4,7-8H2,1H3; Key:DOWVMJFBDGWVML-UHFFFAOYSA-N;

BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. It interacts with the human endocannabinoid system. The drug was in development for the treatment of a range of different medical conditions from anxiety disorder to Parkinson's disease, also for the treatment of chronic pain of multiple sclerosis, cancer, hypertension or the treatment of obesity. A clinical trial with this drug was underway in Rennes, France, in January 2016, in which serious adverse events occurred affecting five participants, including the death of one man. The underlying mechanism that caused the acute neurotoxicity of this molecule remains unknown.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.